Tylenol maker Kenvue plunges on reports that the White House planned to link the drug to autism

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

What is Kenvue? The Tylenol maker facing RFK Jr. scrutiny over autism claims

Tylenol, a popular over-the-counter pain reliever whose active ingredient is acetaminophen, is made by Kenvue, a spinoff of Johnson & Johnson. In early spring, the company moved its global headquarters to New Jersey, cutting the ribbon on the new location with Gov. Phil Murphy and then-Kenvue CEO Thibaut Mongon.
STAT

Pharmalittle: We’re reading about a GSK drug reapproved for autism, Kenvue’s Tylenol nightmare, and more

The FDA reapproved a GSK drug that stopped being sold more than 25 years ago, as part of a push to identify potential treatments for autism

Kenvue: This Too Shall Pass

Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.

Tylenol-maker Kenvue shares bounce back, Trump claims face pushback

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.
Feedback